AI Article Synopsis

  • Spirooxindole-1,3-oxazines are a rare group of alkaloids, with only four known to be found in nature, and their biological roles remain largely unexplored.
  • Dioxyreserpine, a synthetic derivative of the natural alkaloid (-)-reserpine, has been identified as a moderate antitumoral agent and is synthesized through a specific catalytic process.
  • Further structural modifications of dioxyreserpine resulted in potent and selective growth inhibitors for various human cancers, achieving effective low-micromolar IC-values and inducing targeted cell death in cancer cells.

Article Abstract

Spirooxindole-1,3-oxazines are a small and structurally unique class of spirooxindole alkaloids. To date, only four of these compounds have been isolated from natural sources, and their biological properties remained unknown thus far. Dioxyreserpine is a synthetic spirooxindole-1,3-oxazine, that can readily be prepared from the Rauvolfia alkaloid (-)-reserpine by catalytic photooxygenation. While dioxyreserpine itself was now identified as a moderately effective antitumoral agent, structurally modified analogs of it emerged as a new class of highly potent and selective growth inhibitors of various human cancers, including pancreatic cancers. Systematic structural optimization ultimately led to an inhibitor displaying low-micromolar IC -values against six cancer cell lines as well as selective apoptosis induction in vitro.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400852PMC
http://dx.doi.org/10.1002/cmdc.202200162DOI Listing

Publication Analysis

Top Keywords

highly potent
8
potent selective
8
spirooxindol-13-oxazine alkaloids
4
alkaloids highly
4
selective antitumor
4
antitumor agents
4
agents evolved
4
evolved iterative
4
iterative structure
4
structure optimization
4

Similar Publications

Discovery of Potent, Highly Selective, and Orally Bioavailable MTA Cooperative PRMT5 Inhibitors with Robust Antitumor Activity.

J Med Chem

January 2025

Insilico Medicine Shanghai Ltd, Suite 901, Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China.

Protein arginine methyltransferase 5 (PRMT5), which catalyzes the symmetric dimethylation of arginine residues on target proteins, plays a critical role in gene expression regulation, RNA processing, and signal transduction. Aberrant PRMT5 activity has been implicated in cancers and other diseases, making it a potential therapeutic target. Here, we report the discovery of a methylthioadenosine (MTA) cooperative PRMT5 inhibitor.

View Article and Find Full Text PDF

Developing Topics.

Alzheimers Dement

December 2024

Pharmaceutical Sciences, Roche Pharma Research and Early Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Background: γ-Secretase modulators (GSMs) represent a promising therapy for Alzheimer's disease (AD). GSMs selectively reduce amyloidogenic long Aβ peptides (e.g.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Biosplice Therapeutics, Inc., San Diego, CA, USA.

Background: DYRK1A overexpression, common in neurodegenerative diseases like Alzheimer's (AD), contributes to neurofibrillary tangles via Tau protein hyperphosphorylation and amyloid plaque formation, key AD hallmarks. Therefore, DYRK1A has been regarded as a novel target for neurodegenerative diseases. However, developing DYRK1A selective inhibitors has been a difficult challenge due to the highly conserved ATP-binding site of protein kinases, particularly among the CMGC family.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Vigil Neuroscience, Inc, Watertown, MA, USA.

Background: TREM2 is a lipid-sensing receptor expressed by microglial sub-populations within neuropathological microenvironments, whose downstream signaling promotes microglial survival, plasticity, and migration. Multiple loss-of-function variants strongly implicate TREM2 as a key regulator of Alzheimer's disease (AD) risk. Accordingly, TREM2 antibodies are currently in development to evaluate the therapeutic potential of TREM2 agonism in neurodegenerative diseases.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.

Background: Alzheimer disease (AD) is a progressive neurodegenerative disease that is accountable for the leading case of dementia in elder people. Before, only symptomatic treatments are available for AD. Since 2021, two anti-amyloid antibodies aducanumab and lecanemab have been approved by the US Food and Drug Administration.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!